Table 4. Characteristics of studies reviewed with invasive pneumococcal disease as endpoint.
| Author, year | Country | Vaccine | Study design | Case definition | Data source | Age * groups | Years of baseline data | Baseline measure (Rates p. 100,000) | Years of post PCV introduction data | Percent change/ effectiveness | Statistical Significance (95% CI or p-value) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Valenzuela, 2014 [45], ISPC, 2015 [46] | Chile | PCV-10 | Interrupted time series | Spn$ isolated from normally sterile fluids | National Reference Laboratory | 0–35m | 2007–2010 | 24.6 | 2012 | 56.9 | Not available |
| Garcia Gabarrot, 2014 [44] | Uruguay | PCV-13 | Before-after | Spn isolated from normally sterile fluids | National Reference Laboratory | <24m | 2003–2007 | 68.7; 24.8# | 2009–2012 | 66.0; 75.0# | 46–79; 39–90# |
| 24–60m | 2003–2007 | 23.8; 16.0# | 2009–2012 | 57.0; 56.0# | 9–79; -6.3–82.0# | ||||||
| Domingues, 2014 [15, 43] Verani, 2015 [16] | Brazil | PCV-10 | Case control | Spn isolated from normally sterile fluids | Cases: National laboratory surveillance; Controls: National birth registry | 2–53.1m | 2010#a | 316 cases and 1,219 controls | 2.7#b | 83.8# | 65.9–92.3# |
| Andrade, 2015 [47] 2016[32] | Brazil | PCV-10 | Interrupted time series | Spn isolated from normally sterile fluids | National Notifiable Diseases Surveillance System; National reference laboratory | 2–23m | Jan. 2008—Dec. 2009 | 20.9§ | Jan. 2011 Dec. 2013 | 44.2 | 15.8–72.5 |
| 2–11m | 29.2§ | 34.7 | 10.4–58.9 | ||||||||
| 12–23m | 13.8§ | 61.1 | 39.6–82.7 | ||||||||
| 24–60m | 3.9§ | -14.7 | -115.1–85.7 |
* Age groups with results of interest for this study
# VT-PCV-13
#a: Start of case detection
#b: Duration of follow-up/case detection
§ Predicted rates based on time-series modeling
$ S. pneumonia